期刊
ORGANIC PROCESS RESEARCH & DEVELOPMENT
卷 24, 期 11, 页码 2780-2788出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.oprd.0c00412
关键词
FXI inhibitor; biocatalysis; continuous manufacturing; surfactant; scale-up
资金
- Novartis, Inc.
The scalable synthesis of an FXI (Factor XI) inhibitor employing multiple emerging technologies is described. The reduction of ketone to chiral alcohol was established through a biocatalysis approach. The Suzuki-Miyaura cross-coupling reaction was facilitated by surfactant chemistry. A harsh hydrolysis of the nitrile was performed in a continuous manufacturing mode. Extensive reaction optimization and process development led to a well-controlled protocol for scale-up. The alternative approach described here addressed issues from the discovery route and was utilized to deliver the desired target for preclinical studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据